FATEFate Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.44 · now $2.44 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, FATE has typically landed between $1.58 and $3.63 — a range of −35.2% to +48.8% from the issuance price $2.44.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,237 overlapping 1 month windows · 2013-10-012026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.44) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where FATE has typically landed a month from the 2026-09-16 close of $2.44 — the range is history, not a prediction.

$1.58worst · -35.2%$3.63best · +48.8%
  • now $2.44 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.27 (-7.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.9$2.64
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.58$3.63
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,237 windows spanning 2013-10-01 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-12-06−72.5%−72.5%+0.0%
2022-12-07−71.3%−72.4%+0.1%
2022-12-08−70.1%−72.4%+0.0%
3 best
2026-04-29+129.0%+0.0%+129.0%
2026-04-30+119.2%+0.0%+127.2%
2026-04-08+105.9%+0.0%+105.9%

3,237 overlapping windows · 2013-10-012026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~13 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
54%
+4.9%
n=13
Feb
62%
+7.8%
n=13
Mar
46%
−2.1%
n=13
Apr
62%
+0.4%
n=13
May
46%
+7.1%
n=13
Jun
54%
+0.5%
n=13
Jul
38%
+3.9%
n=13
Aug
31%
−2.5%
n=13
Sep
46%
+0.2%
n=13
Oct
25%
−9.2%
n=12
Nov
54%
+9.1%
n=13
Dec
54%
+4.5%
n=13

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-08-04: 2 insider sales, $204K — Valamehr Bahram, TAHL CINDY2026-05-20: 2 insider sales, $103K — Valamehr Bahram, TAHL CINDY2026-01-09: 2 insider sales, $17K — TAHL CINDY, Valamehr Bahram2025-08: 2 open-market sales, $25K2026-01: 2 open-market sales, $17K2026-05: 2 open-market sales, $103K2026-08: 2 open-market sales, $204K↑ buys↓ salesdirector Valamehr Bahram — Sale on 2026-08-04, filed 1 day after the tradeofficer TAHL CINDY — Sale on 2026-08-04, filed 1 day after the tradedirector Valamehr Bahram — Sale on 2026-05-20, filed 1 day after the tradeofficer TAHL CINDY — Sale on 2026-05-20, filed 1 day after the tradeofficer TAHL CINDY — Sale on 2026-01-09, filed 3 days after the tradedirector Valamehr Bahram — Sale on 2026-01-09, filed 3 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-08-04Valamehr BahramdirectorSale43,947 @ $2.46$108K−6.9% of holding−3.9%not yet — horizon still open591,815Form 4 · filed 1 day after the trade
2026-08-04TAHL CINDYofficerSale38,800 @ $2.46$95K−6.2% of holding−3.9%not yet — horizon still open589,355Form 4 · filed 1 day after the trade
2026-05-20Valamehr BahramdirectorSale28,946 @ $1.88$54K−4.4% of holding+16.2%not yet — horizon still open635,762Form 4 · filed 1 day after the trade
2026-05-20TAHL CINDYofficerSale25,590 @ $1.88$48K−3.9% of holding+16.2%not yet — horizon still open628,155Form 4 · filed 1 day after the trade
2026-01-09TAHL CINDYofficerSale10,589 @ $1.06$11K−2.7% of holding+4.1%+175.9%387,081Form 4 · filed 3 days after the trade
2026-01-09Valamehr BahramdirectorSale5,190 @ $1.07$6K−1.5% of holding+4.1%+175.9%329,708Form 4 · filed 3 days after the trade
2025-08-04Valamehr BahramdirectorSale14,466 @ $1.06$15K−4.1% of holding−7.7%−0.4%334,898Form 4 · filed 1 day after the trade
2025-08-04TAHL CINDYofficerSale9,037 @ $1.06$10K−2.2% of holding−7.7%−0.4%397,670Form 4 · filed 1 day after the trade
2025-01-10Valamehr BahramdirectorSale8,705 @ $1.54$13K−2.4% of holding−22.0%−30.9%349,364Form 4 · filed 3 days after the trade
2025-01-10Bressi Jerome CharlesofficerSale5,980 @ $1.55$9K−2.2% of holding−22.0%−30.9%270,203Form 4 · filed 3 days after the trade
2025-01-10TAHL CINDYofficerSale5,654 @ $1.55$9K−1.7% of holding−22.0%−30.9%336,707Form 4 · filed 3 days after the trade
2024-12-20Redmile Group, LLCdirectorPurchase397,964 @ $1.68$669K+3.2% of holding−23.7%−38.6%12,884,277Form 4 · filed 6 days after the trade
2024-12-20Redmile Group, LLCdirectorSale341,633 @ $1.68$574K−2.7% of holding−23.7%−38.6%12,486,313Form 4 · filed 6 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

59 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-12ABERNETHY MATTdirectorAward / grant87,90087,900Form 4
2026-06-12Agarwal ShefalidirectorAward / grant87,90087,900Form 4
2026-06-12EPSTEIN ROBERT SdirectorAward / grant87,90087,900Form 4
2026-06-12Lee Michael StewartdirectorAward / grant87,90087,900Form 4
2026-06-12Redmile Group, LLCdirectorAward / grant87,90087,900Form 4
2026-06-12Hamill LauradirectorAward / grant175,800175,800Form 4
2026-06-12RASTETTER WILLIAM HdirectorAward / grant87,90087,900Form 4
2026-06-12Jooss KarindirectorAward / grant87,90087,900Form 4
2026-06-12Xu YuandirectorAward / grant87,90087,900Form 4
2026-05-06TAHL CINDYofficerOption exercise122,220609,301Form 4
2026-05-06TAHL CINDYofficerOption exercise44,444653,745Form 4
2026-05-06TAHL CINDYofficerOption exercise44,444355,556Form 4
2026-05-06TAHL CINDYofficerOption exercise122,220152,780Form 4
2026-05-05EPSTEIN ROBERT SdirectorOption exercise25,00036,331Form 4
2026-05-05RASTETTER WILLIAM HdirectorOption exercise25,00036,331Form 4
2026-05-05EPSTEIN ROBERT SdirectorOption exercise25,0000Form 4
2026-05-05RASTETTER WILLIAM HdirectorOption exercise25,0000Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition8,977,62412,884,277Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition162,0130Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition162,0132,755,086Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition8,977,6240Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition3,691,3240Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition3,691,3243,893,674Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition266,2800Form 4
2026-04-20Redmile Group, LLCdirectorOther acquisition266,280502,769Form 4
2026-01-15TAHL CINDYofficerAward / grant100,000487,081Form 4
2026-01-15TAHL CINDYofficerAward / grant400,000400,000Form 4
2026-01-15Valamehr BahramdirectorAward / grant335,000664,708Form 4
2026-01-15Adawi KamalofficerAward / grant25,000100,000Form 4
2026-01-15Valamehr BahramdirectorAward / grant1,300,0001,300,000Form 4
2026-01-15Adawi KamalofficerAward / grant75,00075,000Form 4
2025-10-20Adawi KamalofficerAward / grant75,00075,000Form 4
2025-10-20Adawi KamalofficerAward / grant375,000375,000Form 4
2025-05-29RASTETTER WILLIAM HdirectorAward / grant55,00055,000Form 4
2025-05-29MENDLEIN JOHNdirectorAward / grant55,00055,000Form 4
2025-05-29Redmile Group, LLCdirectorAward / grant55,00055,000Form 4
2025-05-29Agarwal ShefalidirectorAward / grant55,00055,000Form 4
2025-05-29ABERNETHY MATTdirectorAward / grant110,000110,000Form 4
2025-05-29EPSTEIN ROBERT SdirectorAward / grant55,00055,000Form 4
2025-05-29Lee Michael StewartdirectorAward / grant55,00055,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.